Literature DB >> 7554032

Transgenic and gene knockout mice in cancer research.

J L Viney1.   

Abstract

Transgenic animal technology, and the use of germline manipulation for the creation of targeted gene mutations, has resulted in a plethora of murine models for cancer research. Our understanding of some of the important issues regarding the mechanisms controlling cell division, differentiation and death has dramatically advanced in recent years through exploitation of these techniques to generate transgenic mice. In particular, the generation of mice with targeted mutations in genes encoding proteins of oncological interest has proved to be a useful way of elucidating the function of these gene products in vivo. Transgenic mouse models have provided some insight into the complex oncogenic events contributing to cellular dysregulation and the loss of growth control that can lead to tumorigenesis. These animal studies have highlighted the fact that there are many different stages at which the loss of cell cycle control can occur, as a result of mutations affecting proteins anywhere from the cell surface to the nucleus. Although mutations affecting growth factors, growth factor receptors, signal transduction molecules, cytoplasmic proteins or nuclear proteins might appear to be very distinct, the end result of these changes may be accelerated and unchecked cell growth ultimately leading to cancer. It is beyond the scope of this review to mention every animal model that has been developed for cancer research, especially since many of the early studies have been covered extensively in previous reviews. This article will instead focus on a small selection of transgenic and knockout animal models which exemplify how proteins from distinct localisations along multiple pathways can contribute to loss of cell cycle control and the pathogenesis of cancer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7554032     DOI: 10.1007/bf00665792

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  79 in total

Review 1.  Transforming growth factor-alpha: an oncodevelopmental growth factor.

Authors:  D S Salomon; N Kim; T Saeki; F Ciardiello
Journal:  Cancer Cells       Date:  1990-12

2.  v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid.

Authors:  A Leder; A Kuo; R D Cardiff; E Sinn; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

3.  Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice.

Authors:  Y Matsui; S A Halter; J T Holt; B L Hogan; R J Coffey
Journal:  Cell       Date:  1990-06-15       Impact factor: 41.582

4.  Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis.

Authors:  H Murakami; N D Sanderson; P Nagy; P A Marino; G Merlino; S S Thorgeirsson
Journal:  Cancer Res       Date:  1993-04-15       Impact factor: 12.701

5.  A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice.

Authors:  A C Davis; M Wims; G D Spotts; S R Hann; A Bradley
Journal:  Genes Dev       Date:  1993-04       Impact factor: 11.361

6.  Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice.

Authors:  K Nakayama; K Nakayama; I Negishi; K Kuida; Y Shinkai; M C Louie; L E Fields; P J Lucas; V Stewart; F W Alt
Journal:  Science       Date:  1993-09-17       Impact factor: 47.728

7.  Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors.

Authors:  C J Kemp; L A Donehower; A Bradley; A Balmain
Journal:  Cell       Date:  1993-09-10       Impact factor: 41.582

8.  Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice.

Authors:  C E Rogler; D Yang; L Rossetti; J Donohoe; E Alt; C J Chang; R Rosenfeld; K Neely; R Hintz
Journal:  J Biol Chem       Date:  1994-05-13       Impact factor: 5.157

9.  Acceleration of mammary neoplasia in transforming growth factor alpha transgenic mice by 7,12-dimethylbenzanthracene.

Authors:  R J Coffey; K S Meise; Y Matsui; B L Hogan; P J Dempsey; S A Halter
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

10.  The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells.

Authors:  A W Harris; C A Pinkert; M Crawford; W Y Langdon; R L Brinster; J M Adams
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

View more
  4 in total

1.  Gene targeting approaches using positive-negative selection and large flanking regions.

Authors:  T Thykjaer; J Finnemann; L Schauser; L Christensen; C Poulsen; J Stougaard
Journal:  Plant Mol Biol       Date:  1997-11       Impact factor: 4.076

2.  Loss of giant obscurins promotes breast epithelial cell survival through apoptotic resistance.

Authors:  Nicole A Perry; Marey Shriver; Marie G Mameza; Bryan Grabias; Eric Balzer; Aikaterini Kontrogianni-Konstantopoulos
Journal:  FASEB J       Date:  2012-03-21       Impact factor: 5.191

3.  Simian virus 40 large T antigen and two independent T-antigen segments sensitize cells to apoptosis following genotoxic damage.

Authors:  Sara L Cole; M J Tevethia
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

4.  Development and characterization of a preclinical model of breast cancer lung micrometastatic to macrometastatic progression.

Authors:  Lora C Bailey-Downs; Jessica E Thorpe; Bryan C Disch; Anja Bastian; Paul J Hauser; Taleah Farasyn; William L Berry; Robert E Hurst; Michael A Ihnat
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.